BUSINESSCNBC-TV18 Markets · 18 hours agoLive
Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates
Reported by CNBC-TV18 Markets, not nibnow. We are not the publisher of this story, only the source is.
WHY IT MATTERS
The drop in net profit and revenue signals challenges for Dr Reddy's Laboratories, affecting shareholders and the broader Indian pharmaceutical sector.
WHAT HAPPENED
Dr Reddy’s Laboratories reported a 36% YoY decline in Q2 FY27 net profit to ₹913.4 crore, while revenue fell 1.5% to ₹8,671 crore. The company beat CNBC-TV18 poll estimates for net profit, revenue, EBITDA and EBITDA margin, despite year-on-year declines in profitability and operating margin.
KEY CONTEXT
Dr Reddy's Laboratories is a major Indian drugmaker that reports quarterly financial results, which investors watch to gauge the health of the pharma industry and the company's performance.
WHAT TO WATCH
- •Watch for the company's guidance on Q3 FY27 earnings in its upcoming earnings call
- •Monitor any updates on Lenalidomide sales or new product launches that could affect future revenue
- •Track analyst revisions to price targets based on the latest quarterly performance
Text size
READ IN YOUR LENS
UPSCMarketsFounder